Dry powder inhaler and system for drug delivery

Patent metadata

Field	Value
Publication number	US-10201672-B2
Application number	US-201313933813-A
Country	US
Kind code	B2
Filing date	Jul 2, 2013
Priority date	Jun 13, 2008
Publication date	Feb 12, 2019
Grant date	Feb 12, 2019

Abstract

A breath-powered, dry powder inhaler, a cartridge, and a pulmonary drug delivery system are provided. The dry powder inhaler can be provided with or without a unit dose cartridge for using with the inhaler. The inhaler and/or cartridge can be provided with a drug delivery formulation comprising, for example, a diketopiperazine and an active ingredient, including, peptides and proteins such as insulin, oxyntomodulin and glucagon-like peptide.

First claim

We claim:

1. An inhaler comprising:
a housing, a mouthpiece, and a cartridge contained within the housing, the cartridge comprising two or more rigid parts;
wherein at least one of the two or more rigid parts of the cartridge is a container, wherein the mouthpiece is configured to translocate the container from a powder containment position in a first location to a dosing position in a second location different than the first location by moving the container relative to another of the at least two or more rigid parts of the cartridge thereby creating an entrance into and an exit from the container when in the dosing position;
wherein in the powder containment position, there is not an airflow passageway through the container; and
wherein in the dosing position there is an airflow passageway through the container and 10% to 70% of total airflow through the inhaler enters and exits the cartridge.

2. The inhaler of claim 1 , wherein the mouthpiece is configured to engage a moveable member.

3. The inhaler of claim 1 , further comprising a cartridge housing to accommodate the container.

4. The inhaler of claim 1 , wherein the container is configured to hold a dry powder medicament including at least one active ingredient.

5. The inhaler of claim 4 , wherein the least one active ingredient is a peptide, polypeptide, protein, or a combination thereof.

6. The inhaler of claim 4 , wherein the active ingredient is insulin, glucagon-like peptide 1, oxyntomodulin, peptide YY, exendin, heparin, calcitonin, felbamate, sumatriptan, parathyroid hormone, growth hormone, erythropoietin, AZT, DDI, granulocyte macrophage colony stimulating factor, lamotrigine, chorionic gonadotropin releasing factor, luteinizing releasing hormone, beta-galactosidase, exendin, vasoactive intestinal peptide, an argatroban, anti-SSX-2 41-49 , anti-NY-ESO-1, anti-PRAME, anti-PSMA, anti-Melan-A, anti-tyrosinase, or a combination thereof.

7. The inhaler of claim 4 , wherein the active ingredient is insulin, glucagon-like peptide 1, oxyntomodulin, peptide YY, exendin, analogs thereof, or a combination thereof.

8. The inhaler of claim 4 , wherein the active ingredient is insulin granulocyte macrophage colony stimulating factor (GM-CSF), parathyroid hormone, parathyroid hormone related protein, or parathyroid hormone 1-34.

9. The inhaler of claim 4 , wherein the active ingredient is a neuroactive agent.

10. The inhaler of claim 4 , wherein the active ingredient is oxyntomodulin.

11. The inhaler of claim 4 , wherein the dry powder medicament comprises a diketopiperazine.

12. The inhaler of claim 11 , wherein the diketopiperazine is

13. An inhaler comprising:
a housing a mouthpiece, and a removable cartridge contained within the housing, the cartridge including two or more rigid parts;
wherein at least one of the two or more rigid parts of the removable cartridge is a container, wherein the mouthpiece is configured to translocate the container from a powder containment position in a first location to a dosing position in a second location different than the first location by moving the container relative to another of the at least two or more rigid parts of the cartridge thereby creating an entrance into and an exit from the container when in the dosing position;
wherein in the powder containment position, there is not an airflow passageway through the container; and
wherein in the dosing position there is an airflow passageway through the container and 10% to 70% of total airflow through the inhaler enters and exits the removable cartridge.

14. The inhaler of claim 13 , wherein the mouthpiece is configured to engage a moveable member.

15. The inhaler of claim 1 , further comprising a cartridge housing to accommodate the container.

16. The inhaler of claim 13 , wherein the removable container is configured to hold a dry powder medicament including at least one active ingredient.

17. The inhaler of claim 16 , wherein the least one active ingredient is a peptide, polypeptide, protein, or a combination thereof.

18. The inhaler of claim 16 , wherein the active ingredient is insulin, glucagon-like peptide 1, oxyntomodulin, peptide YY, exendin, heparin, calcitonin, felbamate, sumatriptan, parathyroid hormone, growth hormone, erythropoietin, AZT, DDI, granulocyte macrophage colony stimulating factor, lamotrigine, chorionic gonadotropin releasing factor, luteinizing releasing hormone, beta-galactosidase, exendin, vasoactive intestinal peptide, an argatroban, anti-SSX-2 41-49 , anti-NY-ESO-1, anti-PRAME, anti-PSMA, anti-Melan-A, anti-tyrosinase, or a combination thereof.

19. The inhaler of claim 16 , wherein the active ingredient is insulin, glucagon-like peptide 1, parathyroid hormone, oxyntomodulin, peptide YY, exendin, analogs thereof, or a combination thereof.

20. The inhaler of claim 16 , wherein the active ingredient is granulocyte macrophage colony stimulating factor (GM-CSF), parathyroid hormone, parathyroid hormone related protein, or parathyroid hormone 1-34.

21. The inhaler of claim 16 , wherein the active ingredient is a neuroactive agent, a vasoactive agent, a sedative, an antibiotic, or a vaccine.

22. The inhaler of claim 16 , wherein the active ingredient is oxyntomodulin.

23. The inhaler of claim 16 , wherein the dry powder medicament comprises a diketopiperazine.

24. The inhaler of claim 23 , wherein the diketopiperazine is

25. An inhaler comprising: a housing, a mouthpiece, and a cartridge contained with the housing, the cartridge including two or more rigid parts; wherein at least one of the two or more rigid parts of the cartridge is a container, wherein the mouthpiece is configured to engage a movable member within the housing and translocate the container from a powder containment position in a first location to a dosing position in a second location different than the first location by moving the container relative to another of the at least two or more rigid parts of the cartridge thereby creating an entrance into and an exit from the container when in the dosing position; wherein in the powder containment position, there is not an airflow passageway through the container; wherein in the dosing position there is an airflow passageway through the container and 10% to 70% of total airflow through the inhaler enters and exits the cartridge; and wherein the container is configured to hold a dry powder medicament including insulin and

26. An inhaler comprising: a housing, a mouthpiece, and a removable cartridge contained within the housing, the cartridge including two or more rigid parts; wherein at least one of the two or more rigid parts of the removable cartridge is a container, wherein the mouthpiece is configured to engage the removable cartridge within the housing and translocate the container from a powder containment position in a first location to a dosing position in a second location different than the first location by moving the container relative to another of the at least two or more rigid parts of the removable cartridge thereby creating an entrance into and an exit from the container when in the dosing position; wherein

Assignees

• Mannkind Corp

Inventors

• Smutney Chad C
• Kinsey P Spencer
• Sahi Carl R
• Adamo Benoit
• Polidoro John M
• Mclean Scott
• Overfiled Dennis
• Bryant Anthony

Classifications

• A61M15/0048

  the dosages being arranged in a plane, e.g. on diskettes · CPC title

• A61M2206/20

  having means for promoting or enhancing the flow, actively or passively · CPC title

• A61M15/0043

  Non-destructive separation of the package, e.g. peeling · CPC title

• A61M15/0028 Primary

  using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up · CPC title

• A61M15/0045 Primary

  using multiple prepacked dosages on a same carrier, e.g. blisters · CPC title